DDX41 and breast cancer: Based on immunoprecipitation and western blot analyses using anti-pTyr and anti-CB Abs, we demonstrated that in BC cells, CB is tyrosine phosphorylated at a basal level and that treatment with sorafenib decreases the CB tyrosine phosphorylation levels in a time-dependent manner (% of decrease: 60% and 75% at 1 h and 3 h, respectively) (Fig. 5C).